Warfarin

Generic Name
Warfarin
Brand Names
Coumadin, Jantoven
Drug Type
Small Molecule
Chemical Formula
C19H16O4
CAS Number
81-81-2
Unique Ingredient Identifier
5Q7ZVV76EI
Background

Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.

Indication

Indicated for:

1) Prophylaxis and treatment of venous thromboembolism and related pulmonary embolism.

2) Prophylaxis and treatment of thromboembolism associated with atrial fibrillation.

3) Prophylaxis and treatment of thromboembolism associated with cardiac valve replacement.

4) Use as adjunct therapy to reduce mortality, recurrent myocardial infarction, and thromboembolic events post myocardial infarction.

Off-label uses include:

1) Secondary prevention of stroke and transient ischemic attacks in patients with rheumatic mitral valve disease but without atrial fibrillation.

Associated Conditions
Myocardial Infarction, Pulmonary Embolism, Stroke, Systemic Embolism, Thromboembolism, Transient Ischemic Attack, Venous Thrombosis (Disorder)
Associated Therapies
-

The Study of Warfarin Maintenance Dose in Chinese Patients

First Posted Date
2013-05-16
Last Posted Date
2013-06-04
Lead Sponsor
Chinese Academy of Medical Sciences, Fuwai Hospital
Target Recruit Count
1000
Registration Number
NCT01855737
Locations
🇨🇳

Key Laboratory of Clinical Trial Research in Cardiovascular Drugs, Ministry of Health, Cardiovascular Institute and Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

A Study of Evacetrapib (LY2484595) and Warfarin in Healthy Participants

Phase 1
Completed
Conditions
Interventions
First Posted Date
2013-04-08
Last Posted Date
2018-10-09
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
17
Registration Number
NCT01825876
Locations
🇺🇸

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madison, Wisconsin, United States

AStudy To Evaluate Safety And Eficacy Of Apixaban In Japanese Acute Deep Vein Thrombosis (DVT) And Pulmonary Embolism (PE) Patients

First Posted Date
2013-01-31
Last Posted Date
2016-06-23
Lead Sponsor
Pfizer
Target Recruit Count
80
Registration Number
NCT01780987
Locations
🇯🇵

Toho University Sakura Medical Center, Sakura, Chiba, Japan

🇯🇵

Kokura Memorial Hospital, Kitakyusyu, Fukuoka, Japan

🇯🇵

National Cerebral and Cardiovascular Center Hospital, Suita-shi, Osaka, Japan

and more 17 locations

Safety And Efficacy of Low Dose Oral Anticoagulants And Aspirin Therapy

First Posted Date
2013-01-01
Last Posted Date
2013-01-28
Lead Sponsor
Yasser Elnahas
Target Recruit Count
200
Registration Number
NCT01758640
Locations
🇪🇬

Ain shams University Hospitals, Cairo, Egypt

Compare VKA vs LMWH in Patients With Anticoagulation Criteria and Episode of Gastrointestinal Bleeding.

First Posted Date
2012-11-16
Last Posted Date
2015-09-18
Lead Sponsor
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Target Recruit Count
40
Registration Number
NCT01727453
Locations
🇪🇸

Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

Left Atrial Appendage (LAA) Occluders After Catheter Ablation of Atrial Fibrillation

First Posted Date
2012-09-28
Last Posted Date
2015-07-08
Lead Sponsor
Meshalkin Research Institute of Pathology of Circulation
Target Recruit Count
96
Registration Number
NCT01695824
Locations
🇷🇺

State Research Institute of CIrculation Pathology, Novosibirsk, Russian Federation

Warfarin Versus Aspirin in Patients With Atrial Fibrillation and Chronic Kidney Disease

First Posted Date
2012-08-20
Last Posted Date
2016-10-25
Lead Sponsor
Seoul National University Hospital
Registration Number
NCT01668901
Locations
🇰🇷

Seoul Nationap University Hospital, Seoul, Korea, Republic of

Drug Interaction Study of Isavuconazole and Warfarin in Healthy Male Subjects

First Posted Date
2012-08-06
Last Posted Date
2012-08-28
Lead Sponsor
Astellas Pharma Global Development, Inc.
Target Recruit Count
20
Registration Number
NCT01657825
Locations
🇺🇸

Spaulding Clinical, West Bend, Wisconsin, United States

© Copyright 2024. All Rights Reserved by MedPath